Cargando…

Treatment Response to Botulinum Neurotoxin-A in Children With Cerebral Palsy Categorized by the Type of Stretch Reflex Muscle Activation

While Botulinum NeuroToxin-A (BoNT-A) injections are frequently used to reduce the effects of hyperactive stretch reflexes in children with cerebral palsy (CP), the effects of this treatment vary strongly. Previous research, combining electromyography (EMG) with motion analysis, defined different pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Bar-On, Lynn, Aertbeliën, Erwin, Van Campenhout, Anja, Molenaers, Guy, Desloovere, Kaat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7280486/
https://www.ncbi.nlm.nih.gov/pubmed/32581991
http://dx.doi.org/10.3389/fneur.2020.00378
_version_ 1783543749921472512
author Bar-On, Lynn
Aertbeliën, Erwin
Van Campenhout, Anja
Molenaers, Guy
Desloovere, Kaat
author_facet Bar-On, Lynn
Aertbeliën, Erwin
Van Campenhout, Anja
Molenaers, Guy
Desloovere, Kaat
author_sort Bar-On, Lynn
collection PubMed
description While Botulinum NeuroToxin-A (BoNT-A) injections are frequently used to reduce the effects of hyperactive stretch reflexes in children with cerebral palsy (CP), the effects of this treatment vary strongly. Previous research, combining electromyography (EMG) with motion analysis, defined different patterns of stretch reflex muscle activation in muscles, those that reacted more to a change in velocity (velocity dependent –VD), and those that reacted more to a change in length (length dependent –LD). The aim of this study was to investigate the relation between the types of stretch reflex muscle activation in the semitendinosus with post-BoNT-A outcome as assessed passively and with 3D gait analysis in children with spastic CP. Eighteen children with spastic CP (10 bilaterally involved) between the ages of 12 and 18 years were assessed before and on average, 8 weeks post-treatment. EMG and motion analysis were used to assess the degree and type of muscle activation dependency in the semitendinosus during passive knee extensions performed at different joint angular velocities. Three-dimensional gait analysis was used to assess knee gait kinematics as a measure of functional outcome. Pre-treatment, 9 muscles were classified as VD and 9 as LD, but no differences between the groups were evident in the baseline knee gait kinematics. Post-treatment, stretch reflex muscle activation decreased significantly in both groups but the reduction was more pronounced in those muscles classified pre-treatment as VD (−72% vs. −50%, p = 0.005). In the VD group, these changes were accompanied by greater knee extension at initial contact and during the swing phase of gait. In the LD group, there was significantly increased post-treatment knee hyperextension in late stance. Although results vary between patients, the reduction of stretch reflex muscle activation in the semitendinosus generally translated to an improved functional outcome, as assessed with 3D gait analysis. However, results were less positive for those muscles with pre-treatment length-dependent type of stretch reflex muscle activation. The study demonstrates the relevance of categorizing the type of stretch reflex muscle activation as a possible predictor of treatment response.
format Online
Article
Text
id pubmed-7280486
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-72804862020-06-23 Treatment Response to Botulinum Neurotoxin-A in Children With Cerebral Palsy Categorized by the Type of Stretch Reflex Muscle Activation Bar-On, Lynn Aertbeliën, Erwin Van Campenhout, Anja Molenaers, Guy Desloovere, Kaat Front Neurol Neurology While Botulinum NeuroToxin-A (BoNT-A) injections are frequently used to reduce the effects of hyperactive stretch reflexes in children with cerebral palsy (CP), the effects of this treatment vary strongly. Previous research, combining electromyography (EMG) with motion analysis, defined different patterns of stretch reflex muscle activation in muscles, those that reacted more to a change in velocity (velocity dependent –VD), and those that reacted more to a change in length (length dependent –LD). The aim of this study was to investigate the relation between the types of stretch reflex muscle activation in the semitendinosus with post-BoNT-A outcome as assessed passively and with 3D gait analysis in children with spastic CP. Eighteen children with spastic CP (10 bilaterally involved) between the ages of 12 and 18 years were assessed before and on average, 8 weeks post-treatment. EMG and motion analysis were used to assess the degree and type of muscle activation dependency in the semitendinosus during passive knee extensions performed at different joint angular velocities. Three-dimensional gait analysis was used to assess knee gait kinematics as a measure of functional outcome. Pre-treatment, 9 muscles were classified as VD and 9 as LD, but no differences between the groups were evident in the baseline knee gait kinematics. Post-treatment, stretch reflex muscle activation decreased significantly in both groups but the reduction was more pronounced in those muscles classified pre-treatment as VD (−72% vs. −50%, p = 0.005). In the VD group, these changes were accompanied by greater knee extension at initial contact and during the swing phase of gait. In the LD group, there was significantly increased post-treatment knee hyperextension in late stance. Although results vary between patients, the reduction of stretch reflex muscle activation in the semitendinosus generally translated to an improved functional outcome, as assessed with 3D gait analysis. However, results were less positive for those muscles with pre-treatment length-dependent type of stretch reflex muscle activation. The study demonstrates the relevance of categorizing the type of stretch reflex muscle activation as a possible predictor of treatment response. Frontiers Media S.A. 2020-06-02 /pmc/articles/PMC7280486/ /pubmed/32581991 http://dx.doi.org/10.3389/fneur.2020.00378 Text en Copyright © 2020 Bar-On, Aertbeliën, Van Campenhout, Molenaers and Desloovere. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neurology
Bar-On, Lynn
Aertbeliën, Erwin
Van Campenhout, Anja
Molenaers, Guy
Desloovere, Kaat
Treatment Response to Botulinum Neurotoxin-A in Children With Cerebral Palsy Categorized by the Type of Stretch Reflex Muscle Activation
title Treatment Response to Botulinum Neurotoxin-A in Children With Cerebral Palsy Categorized by the Type of Stretch Reflex Muscle Activation
title_full Treatment Response to Botulinum Neurotoxin-A in Children With Cerebral Palsy Categorized by the Type of Stretch Reflex Muscle Activation
title_fullStr Treatment Response to Botulinum Neurotoxin-A in Children With Cerebral Palsy Categorized by the Type of Stretch Reflex Muscle Activation
title_full_unstemmed Treatment Response to Botulinum Neurotoxin-A in Children With Cerebral Palsy Categorized by the Type of Stretch Reflex Muscle Activation
title_short Treatment Response to Botulinum Neurotoxin-A in Children With Cerebral Palsy Categorized by the Type of Stretch Reflex Muscle Activation
title_sort treatment response to botulinum neurotoxin-a in children with cerebral palsy categorized by the type of stretch reflex muscle activation
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7280486/
https://www.ncbi.nlm.nih.gov/pubmed/32581991
http://dx.doi.org/10.3389/fneur.2020.00378
work_keys_str_mv AT baronlynn treatmentresponsetobotulinumneurotoxinainchildrenwithcerebralpalsycategorizedbythetypeofstretchreflexmuscleactivation
AT aertbelienerwin treatmentresponsetobotulinumneurotoxinainchildrenwithcerebralpalsycategorizedbythetypeofstretchreflexmuscleactivation
AT vancampenhoutanja treatmentresponsetobotulinumneurotoxinainchildrenwithcerebralpalsycategorizedbythetypeofstretchreflexmuscleactivation
AT molenaersguy treatmentresponsetobotulinumneurotoxinainchildrenwithcerebralpalsycategorizedbythetypeofstretchreflexmuscleactivation
AT deslooverekaat treatmentresponsetobotulinumneurotoxinainchildrenwithcerebralpalsycategorizedbythetypeofstretchreflexmuscleactivation